证券代码：688246 证券简称：嘉和美康 公告编号：2025-051 嘉和美康（北京）科技股份有限公司 关于选举第五届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 附件： 1.王春凤女士简历 1983 年 4 月出生，中国国籍，无境外永久居留权，中北大学（分校）学士。 2005年8月至2006年6月任北京众星汇通数码科技有限公司行政人事专员；2006 年 6 月加入嘉和美康（北京）科技股份有限公司，2018 年至今任嘉和美康（北 京）科技股份有限公司人力资源部副经理；2020 年 4 月至 2025 年 7 月任嘉和美 康（北京）科技股份有限公司监事。 王春凤女士未持有公司股份，与公司控股股东、实际控制人、持股 5%以上 股东及其他董事、监事、高级管理人员无关联关系；不存在《中华人民共和国公 司法》规定的不得担任公司的董事、监事、高级管理人员的情形；未被中国证监 会采取证券市场禁入措施；未被证券交易所公开认定为不适合担任上市公司董事、 监事和高级管理人员；未受过中国证监会行政处罚和证券交易所公 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2025-052 嘉和美康（北京）科技股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 07 月 15 日 （二） 股东会召开的地点：北京市海淀区东北旺西路 8 号院 28 号楼 1 层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 118 | | --- | --- | | 普通股股东人数 | 118 | | 2、出席会议的股东所持有的表决权数量 | 83,030,177 | | 普通股股东所持有表决权数量 | 83,030,177 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 60.3480 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 60.348 ...

北京市中伦律师事务所 关于嘉和美康（北京）科技股份有限公司 2025 年第三次临时股东会的 法律意见书 二〇二五年七月 法律意见书 致：嘉和美康（北京）科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会发布的《上 市公司股东会规则》（以下简称"《股东会规则》"）的规定，北京市中伦律师 事务所（以下简称"本所"）接受嘉和美康（北京）科技股份有限公司（以下简 称"公司"）的委托，指派本所律师出席公司 2025 年第三次临时股东会（以下 简称"本次股东会"），对本次股东会的相关事项进行见证并出具法律意见。 为出具本法律意见书，本所律师审查了公司提供的相关文件，该等文件包括 但不限于： 1.现行有效的公司章程； 2.于 2025 年 6 月 27 日、2025 年 7 月 5 日分别发布在上海证券交易所网站 （www.sse.com.cn）上的公司关于召开2025年第三次临时股东会的通知的公告、 关于 2025 年第三次临时股东会增加临时提案的公告； 3.公司本次股东会股权登记日（2025 年 7 月 10 日）的股东 ...

Investment Rating - The report maintains a positive outlook on the computer industry for Q2 2025, indicating an expected improvement in performance [2][4]. Core Insights - The report predicts a gradual recovery in industry profits starting from Q2 2025, with revenue growth rates of 5% and 21% for Q4 2024 and Q1 2025 respectively, and net profit growth rates of -68% and 82% [4][5]. - A total of 55 tracked A-share and Hong Kong-listed computer companies are analyzed, with 13 companies expected to achieve over 50% net profit growth, representing 23.6% of the sample [4][5]. - The report identifies key investment targets across various segments, including AIGC, digital economy leaders, and data innovation [4][5]. Summary by Category Company Performance Predictions - Companies with over 50% net profit growth include: - Jinzheng Co. (4493%) - Zhongke Chuangda (333%) - Zhina Zhen (313%) - Kalait (265%) - Hengsheng Electronics (233%) [4][5][6]. - Companies with 30%-50% net profit growth include: - Dameng Data (48%) - Fanwei Network (39%) - New Point Software (38%) [4][5][6]. - Companies with 0%-30% net profit growth include: - Dongfang Caifu (27%) - Haiguang Information (27%) - Desai Xiwai (27%) [4][5][6]. - Companies with -30% to 0% net profit growth include: - Weining Health (-4%) - Nova Star Cloud (-11%) [4][5][6]. - Companies with less than -30% net profit growth include: - Qiming Star (-30%) - Top Point Software (-36%) [4][5][6]. Key Investment Targets - AIGC Segment: Jinshan Office, Wanxing Technology, Daotong Technology, Hongsoft Technology, and others [4]. - Digital Economy Leaders: Hikvision, Jinshan Office, Hengsheng Electronics, and others [4]. - Data Innovation: Haiguang Information, Ruantong Power, Suocheng Technology, and others [4]. - AIGC Computing Power: Langchao Information, Haiguang Information, and others [4].

Investment Rating - The report indicates a positive investment outlook for the AI healthcare industry, highlighting significant growth potential and increasing investment activity in the sector [3][10][46]. Core Insights - The AI healthcare sector is entering a new phase characterized by multi-modal integration and practical applications, driven by advancements in large models and generative AI [3][7]. - Clinical decision support and drug development are leading the commercialization efforts, while health management remains an area with untapped potential [3][14]. - The report emphasizes the importance of third-party vendors in reducing model hallucination rates and enhancing the reliability of AI applications in healthcare [3][18][21]. Summary by Sections AI Healthcare Trends - The industry is experiencing heightened investment interest and technological advancements, with major players accelerating their presence in the AI healthcare space [9][10][13]. - The integration of AI into clinical workflows is becoming standard, with AI-assisted diagnosis systems deployed in 89% of tertiary hospitals [8][14]. AI Healthcare Application Penetration - AI applications are diversifying across clinical diagnosis, drug development, health management, and AI for science (AI4S), with varying levels of maturity and market potential [30][31]. - The report identifies key areas of application, including intelligent clinical decision support, drug discovery, and personalized health management [36][39]. Key Companies in AI Clinical Diagnosis - Companies like Tempus AI and 嘉和美康 are leading in AI-assisted clinical diagnosis, focusing on electronic medical records and data-driven healthcare solutions [47][51]. - The report highlights the importance of data barriers and scenario positioning in determining the value of AI diagnostic tools [3][46]. Key Companies in AI Health Management - Companies such as 阿里健康 and 京东健康 are leveraging AI to enhance online healthcare services, with a focus on chronic disease management and personalized health plans [39][44]. - The report notes that the integration of insurance and healthcare services is crucial for the growth of AI health management solutions [39][44]. Key Companies in AI Drug Development - The report discusses the role of AI in accelerating drug development processes, with companies like Recursion and 晶泰控股 focusing on preclinical research and drug discovery [38][44]. - AI is expected to significantly reduce the time and cost associated with traditional drug development methods [38][44]. AI4S and Broader Applications - AI4S is identified as a growing field with applications in various scientific domains, including life sciences and materials science, although it faces longer conversion cycles [42][44]. - The report emphasizes the need for innovative approaches to data generation and modeling in AI4S applications [42][44].

Market Performance - As of July 11, the DRG/DIP concept increased by 2.41%, ranking 9th among concept sectors, with 22 stocks rising, including Jiahe Meikang, Weining Health, and Shanda Diwei, which rose by 5.89%, 5.58%, and 4.94% respectively [1] - The top-performing concept sectors today include Rare Earth Permanent Magnet at 5.64% and MLOps at 3.05%, while sectors like Housing Inspection and PCB saw declines of -1.47% and -1.17% respectively [2] Capital Flow - The DRG/DIP concept sector experienced a net inflow of 141 million yuan, with 11 stocks receiving net inflows, and 6 stocks seeing inflows exceeding 10 million yuan. Weining Health led with a net inflow of 190 million yuan, followed by Di'an Diagnosis, Shanda Diwei, and Donghua Software with net inflows of 25.57 million yuan, 20.81 million yuan, and 15.27 million yuan respectively [2] - In terms of capital inflow ratios, Weining Health, Shanda Diwei, and Di'an Diagnosis had the highest net inflow rates at 14.80%, 9.93%, and 7.13% respectively [3] Stock Performance - The top stocks in the DRG/DIP concept based on today's performance include: - Weining Health: 5.58% increase, 6.57% turnover rate, 189.87 million yuan net inflow, 14.80% net inflow ratio - Di'an Diagnosis: 2.23% increase, 4.75% turnover rate, 25.57 million yuan net inflow, 7.13% net inflow ratio - Shanda Diwei: 4.94% increase, 4.32% turnover rate, 20.81 million yuan net inflow, 9.93% net inflow ratio [3][4]

Core Viewpoint - The announcement details a change in shareholder equity for Jiahe Meikang (Beijing) Technology Co., Ltd., specifically regarding the shareholding of Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership), which has reduced its stake to 10.00% following a series of share transactions and stock incentive plans [1][2][3]. Summary by Sections 1. Basic Information of the Shareholder - Guoshou Chengda is a limited partnership with a registered capital of 12.01 billion yuan, primarily engaged in equity investment and asset management [1]. - The partnership was established on November 11, 2016, and is managed by Guoshou Chengda (Shanghai) Health Medical Equity Investment Management Co., Ltd. [1]. 2. Details of the Equity Change - Guoshou Chengda executed a share reduction plan, resulting in a total reduction of 3,053,509 shares, bringing its holdings down to 13,758,560 shares, which is 10.00% of the total share capital [2][3]. - The total share capital of the company has changed from 137,877,502 shares to 137,585,598 shares due to the issuance of restricted stocks and stock options [2][3]. 3. Shareholding Situation Before and After the Change - Before the equity change, Guoshou Chengda held 19,569,619 shares, representing 14.1935% of the total share capital [3]. - After the equity change, Guoshou Chengda's holdings decreased to 13,758,560 shares, which is 10.00% of the total share capital [3]. 4. Future Matters - The equity change aligns with previously disclosed plans and commitments by the shareholder [2]. - The company will continue to comply with relevant disclosure regulations and ensure timely updates to investors regarding any further changes [2].

嘉和美康（北京）科技股份有限公司 简式权益变动报告书 上市公司名称：嘉和美康（北京）科技股份有限公司 股票上市地点：上海证券交易所 股票简称：嘉和美康 股票代码：688246 信息披露义务人名称：国寿成达（上海）健康产业股权投资中心（有限合伙） 注册地址：中国（上海）自由贸易试验区银城路 88 号 39 楼 06 单元 通讯地址：北京市朝阳区东三环中路 5 号财富金融中心 67 层 邮政编码：100020 股份变动性质：股份减少 简式权益变动报告书签署日期：2025 年 7 月 3 日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》 （以下简称"《证券法》"）、 《上市公司收购管理办法》 （以下简称"《收购办法》"）、 《公开发行证券的公司信 息披露内容与格式准则第 15 号——权益变动报告书》（以下简称"准则 15 号"） 及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》、准则 15 号的规定，本报告书已全面披露 了信息披露义务人在嘉和美康（北京 ...

证券代码:688246 证券简称:嘉和美康 公告编号：2025-049 嘉和美康（北京）科技股份有限公司 关于修订公司章程的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉和美康（北京）科技股份有限公司（以下简称"公司"）于 2025 年 7 月 份有限公司 2025 年第三次临时股东会增加临时提案的函》，根据公司实际经营 情况和发展需要，公司新设联席总经理岗位，相应修订公司章程，本事项尚需提 交 2025 年第三次临时股东会审议。具体情况如下： 一、修订《公司章程》的原因 根据公司实际经营情况和发展需要，公司新设联席总经理岗位，相应修订公 司章程。 二、《公司章程》修订情况 修订前 修订后 第十二条 本章程所称高级管理人员是 第十二条 本章程所称高级管理人员 指公司的总经理、副总经理、财务负责 是指公司的总经理、联席总经理、副 人、董事会秘书和本章程规定的其他人 总经理、财务负责人、董事会秘书和 员。 本章程规定的其他人员。 第一百一十一条 董事会行使下列职 第一百一十一条 董事会行使下列职 权： 权： …… … ...

嘉和美康（北京）科技股份有限公司 简式权益变动报告书 上市公司名称：嘉和美康（北京）科技股份有限公司 股票上市地点：上海证券交易所 股票简称：嘉和美康 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券的公司信 息披露内容与格式准则第 15 号——权益变动报告书》（以下简称"准则 15 号"） 及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》、准则 15 号的规定，本报告书已全面披露 了信息披露义务人在嘉和美康（北京）科技股份有限公司中拥有权益的股份变动 情况。 四、截至本报告书签署之日，除本报告书披露的持股信息外，信息披露义务 人没有通过任何其他方式增加或减少其在嘉和美康（北京）科技股份有限公司中 拥有权益的股份。 五、本次权益变动是根据本报告书所载明的资料进行的。信息披露义务人没 有委托或者授权其他任何人提供未在本报告书中列载的信息和对本报告书做出 任 ...